Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02772679 · ClinicalTrials.gov registry record · Phase 1

T1DM Immunotherapy Using Polyclonal Tregs + IL-2

A Phase 1 study of Type 1 Diabetes Mellitus, sponsored by Jeffrey Bluestone.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
2
Study locations

NCT02772679 is a Phase 1 study of Type 1 Diabetes Mellitus that has completed, run by Jeffrey Bluestone. The registered enrollment target is 16 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02772679, a Phase 1 study of Type 1 Diabetes Mellitus, has completed, sponsored by Jeffrey Bluestone.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to assess the safety of Tregs + IL-2 and survival of Tregs in patients with recent onset T1DM who receive infusions of autologous Tregs + IL-2.

Conditions Studied

Type 1 Diabetes Mellitus

Interventions

  • BIOLOGICAL PolyTregs+IL-2

Study Locations (2)

California

  • University of California, San Francisco Medical Center - San Francisco

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2016-08
Est. Completion 2021-08-27
Phase Phase 1

Sponsor

Jeffrey Bluestone

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02772679

The ClinicalTrials.gov registry entry for NCT02772679 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (89% lower). The listed sponsor is Jeffrey Bluestone, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which PolyTregs+IL-2 is the first listed.

NCT02772679 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT02772679 about?

NCT02772679 is a clinical study titled "T1DM Immunotherapy Using Polyclonal Tregs + IL-2". The purpose of this study is to assess the safety of Tregs + IL-2 and survival of Tregs in patients with recent onset T1DM who receive infusions of autologous Tregs + IL-2.

What is the current status of trial NCT02772679?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-08. Estimated completion is 2021-08-27.

What conditions does trial NCT02772679 study?

This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.

What interventions are being tested in trial NCT02772679?

The interventions under investigation include: PolyTregs+IL-2 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02772679?

This trial is sponsored by Jeffrey Bluestone, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02772679 being conducted?

This trial has 2 study locations across California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 1 Diabetes Mellitus

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.